Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
-
- Benjamin L. Sievers
- J. Craig Venter Institute, La Jolla, CA 92037, USA.
-
- Saborni Chakraborty
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
-
- Yong Xue
- J. Craig Venter Institute, Rockville, MD 20850, USA.
-
- Terri Gelbart
- J. Craig Venter Institute, La Jolla, CA 92037, USA.
-
- Joseph C. Gonzalez
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
-
- Arianna G. Cassidy
- Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA 94115, USA.
-
- Yarden Golan
- Department of Bioengineering and Therapeutic Sciences, and Institute for Human Genetics, University of California, San Francisco, San Francisco, CA 94115, USA.
-
- Mary Prahl
- Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94115, USA.
-
- Stephanie L. Gaw
- Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA 94115, USA.
-
- Prabhu S. Arunachalam
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
-
- Catherine A. Blish
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
-
- Scott D. Boyd
- Departments of Pathology and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
-
- Mark M. Davis
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
-
- Prasanna Jagannathan
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
-
- Kari C. Nadeau
- Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA 94305, USA.
-
- Bali Pulendran
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
-
- Upinder Singh
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
-
- Richard H. Scheuermann
- J. Craig Venter Institute, La Jolla, CA 92037, USA.
-
- Matthew B. Frieman
- Department of Microbiology and Immunology, Center for Pathogen Research, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
-
- Sanjay Vashee
- J. Craig Venter Institute, Rockville, MD 20850, USA.
-
- Taia T. Wang
- Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.
-
- Gene S. Tan
- J. Craig Venter Institute, La Jolla, CA 92037, USA.
説明
<jats:p>Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that have mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.1.529) spike protein appear to diminish the protection conferred by preexisting immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing the spike protein of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in individuals after infection and in mRNA-vaccinated individuals. We observed that boosting increases the magnitude of the antibody response to wild-type (D614), Beta, Delta, and Omicron variants; however, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses, whereas responses may have been reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines.</jats:p>
収録刊行物
-
- Science Translational Medicine
-
Science Translational Medicine 14 (634), 2022-03-02
American Association for the Advancement of Science (AAAS)